Divestiture News & Analysis
4 articles
Market Mood
BP to Sell North Sea Business Ending 60 Years of UK Production
BP (BP) plans to sell its North Sea business, marking the end of its 60-year history in UK oil production. This move is part of BP's strategy to refocus its operations amid changing market dynamics. The company has been divesting oil and gas assets as it shifts towards renewable energy solutions. For investors, this significant shift could signal important changes in BP's future earnings potential and operational focus.
Read More: BP to Sell North Sea Business Ending 60 Years of UK Production
Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Eli Lilly (LLY) has reported significant financial benefits from its GLP-1 drug line, although specific figures are not detailed. Honeywell (HON) has made the strategic decision to divest a lower-margin unit, aiming to enhance overall profitability. This move could impact both companies' profit margins as LLY capitalizes on a high-demand market while HON restructures its operations. The market may see a shift as investors evaluate the potential growth of LLY and the implications of HON's divestiture.
Read More: Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Edwards Lifesciences Trading at $83.92 with Strong Growth Prospects
As of March 16, 2026, Edwards Lifesciences Corporation's share price was $83.92, with a trailing P/E of 46.17 and a forward P/E of 28.49. The company completed a $4.2 billion divestiture of its Critical Care business, which affected approximately 20% of its 2023 EBITDA base. However, the Transcatheter Mitral and Tricuspid Therapies segment is growing over 50% year-over-year, while the Transcatheter Aortic Valve Replacement franchise generates over $4.5 billion in annual revenue with 12%+ growth. Edwards Lifesciences has a strong balance sheet, holding $3.8 billion in cash and is trading at a valuation of approximately 21.3x EV/NTM EBITDA, below its historical average of 26x.
Read More: Edwards Lifesciences Trading at $83.92 with Strong Growth Prospects
PTC Completes $523M Sale of Kepware & ThingWorx, Raises FY2026 Cash Flow
PTC has completed the sale of its Kepware and ThingWorx businesses for $523 million, resulting in net after-tax proceeds of $375 million and a gain of $464 million. The company raised its fiscal 2026 free cash flow guidance to $850 million, despite an anticipated cash flow headwind of approximately $70 million in FY27 due to a transition services agreement with TPG. PTC plans to allocate $1.125 to $1.225 billion for share repurchases. This divestiture allows PTC to focus more on its intelligent product lifecycle vision.
Read More: PTC Completes $523M Sale of Kepware & ThingWorx, Raises FY2026 Cash Flow